Tackling cancer
From discovery to development to delivery of transformational therapies and technological solutions, we are collaborating with the brightest minds to advance the next wave of treatments—and potential cures.
Our transformative portfolio is setting new standards of care for some of the most difficult to treat cancers, including multiple myeloma, B-cell malignancies, bladder cancer, prostate cancer, and lung cancer. Through the convergence of our innovative medicine and medical device expertise and technology, we are striving to change the future of cancer.
Innovating in Health&Care
-
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this personalized therapy. -
5 things we now know about prostate cancer
This disease is highly treatable if caught early—but in its earliest stages, prostate cancer often has no symptoms, allowing it to develop without detection. Learn more about this common cancer and how Johnson & Johnson is innovating across both early-stage and advanced disease.
-
5 ways Johnson & Johnson is innovating in medicines and therapies
From rare diseases to all-too-common cancers, Johnson & Johnson is on a mission to improve treatment options for people around the globe. Learn more about how the company is working to create new therapies for IBD, lung cancer, major depressive disorder, bladder cancer, myasthenia gravis and more. -
Understanding head and neck cancer
This complex type of cancer can cause malignancies of the mouth, throat, larynx and nasal cavity. Find out how Johnson & Johnson is innovating to change the current treatment paradigm.
-
Striving for a cure for multiple myeloma
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer. -
What is acute myeloid leukemia?
It’s the most common type of acute leukemia in adults, yet it has the lowest survival rate of all leukemias. Learn more about this difficult-to-treat blood cancer and why Johnson & Johnson is on a mission to deliver better treatment options.
-
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy. -
“Our goal is a solution for every bladder cancer patient”
Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world. -
What is a gene mutation?
Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. Learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.
Our oncology disease areas
-
Find information about clinical trials
Read moreYou are now leaving jnj.com.
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. Click continue to proceed.
You are now leaving jnj.com.
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. Click continue to proceed.
-
Learn about our development pipeline
Read moreYou are now leaving jnj.com.
This link will take you to a different Johnson & Johnson website, where different laws and regulations may apply.
You are now leaving jnj.com.
This link will take you to a different Johnson & Johnson website, where different laws and regulations may apply.